Video

Dr. Alvarnas on Stem Cell Transplant for HIV-Associated Lymphoma

Author(s):

Joseph Alvarnas, MD

In Partnership With:

Joseph Alvarnas, MD, the director of Medical Quality at City of Hope National Medical Center, discusses autologous hematopoietic stem cell transplantation (AHCT) for patients with HIV-associated lymphoma.

Joseph Alvarnas, MD, the director of Medical Quality at City of Hope National Medical Center, discusses autologous hematopoietic stem cell transplantation (AHCT) for patients with HIV-associated lymphoma.

A​ recent phase II study compared HIV-associated lymphoma with lymphoma patients without HIV and found that both groups had similar outcomes after AHCT. The one-year survival rate for the HIV-lymphoma patients was 86%.

This research is extremely promising, says Alvarnas, because it was previously believed that those with HIV-associated lymphoma could not undergo transplant safely and were instead treated with minimal chemotherapy or less intense therapies.

Related Videos
Odzer on ERBB2 Copy Number Ratio as a Predictive Biomarker in HER2+ Breast Cancer
Robert M. Rifkin, MD, FACP
Renier Brentjens, MD, PhD,
Jian Zhang, MD
Carsten Niemann, MD, PhD, chief physician, and head of Laboratory at the Rigshospitalet Copenhagen University Hospital.
Jae Park, MD
David A. Braun, MD, PhD
Bradley McGregor, MD,
Francisco J. Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine – Lymphoma, director, Lymphoma Research, head, Lymphoma Translational Research Lab, associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Related Content
US FDA
January 16th 2025

Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, the Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Susan M. O'Brien, MD, associate director, Clinical Science, Chao Family Comprehensive Cancer Center, medical director, Sue & Ralph Stern Center for Clinical Trials & Research, professor, medicine, Division of Hematology/Oncology, University of California Irvine School of Medicine
December 31st 2024

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

Michael T. Tees, MD, MPH, of Colorado Blood Cancer Institute
January 12th 2025

BTK Degraders Look to Fill Unmet Need for Patients With Pretreated B-Cell Malignancies

Alex F. Herrera, MD, chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, associate medical director, Briskin Center for Clinical Research, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
December 13th 2024

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

Armin Ghobadi, MD
January 7th 2025

WT-7 Shows Acceptable Safety Profile in Relapsed/Refractory T-ALL/LBL

NCCN: Image by Kellie Ehrmann/MJH Life Sciences using AI
December 31st 2024

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies